Exploring hematoma expansion shift with recombinant factor VIIa: a pooled analysis of 4 randomized controlled trials
BACKGROUND: - Hematoma expansion shift (HES) analysis can be used to assess the biological effect of a hemostatic therapy for intracerebral hemorrhage. In this study, we applied HES analysis to individual patient data from 4 randomized controlled trials evaluating rFVIIa (recombinant factor VIIa) 80...
Gespeichert in:
| Hauptverfasser: | , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
Dec 2023
|
| In: |
Stroke
Year: 2023, Jahrgang: 54, Heft: 12, Pages: 2990-2998 |
| ISSN: | 1524-4628 |
| DOI: | 10.1161/STROKEAHA.123.043209 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1161/STROKEAHA.123.043209 Verlag, lizenzpflichtig, Volltext: https://www.ahajournals.org/doi/10.1161/STROKEAHA.123.043209 
|
| Verfasserangaben: | Vignan Yogendrakumar, MD, MSc; Stephan A. Mayer, MD; Thorsten Steiner, MD, PhD; Joseph P. Broderick, MD; Dar Dowlatshahi, MD, PhD |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1885254652 | ||
| 003 | DE-627 | ||
| 005 | 20240703162952.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240408s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1161/STROKEAHA.123.043209 |2 doi | |
| 035 | |a (DE-627)1885254652 | ||
| 035 | |a (DE-599)KXP1885254652 | ||
| 035 | |a (OCoLC)1443668223 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Yogendrakumar, Vignan |e VerfasserIn |0 (DE-588)1325511781 |0 (DE-627)1885255454 |4 aut | |
| 245 | 1 | 0 | |a Exploring hematoma expansion shift with recombinant factor VIIa |b a pooled analysis of 4 randomized controlled trials |c Vignan Yogendrakumar, MD, MSc; Stephan A. Mayer, MD; Thorsten Steiner, MD, PhD; Joseph P. Broderick, MD; Dar Dowlatshahi, MD, PhD |
| 264 | 1 | |c Dec 2023 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Veröffentlicht am 8. Oktober 2023 | ||
| 500 | |a Gesehen am 08.04.2024 | ||
| 520 | |a BACKGROUND: - Hematoma expansion shift (HES) analysis can be used to assess the biological effect of a hemostatic therapy for intracerebral hemorrhage. In this study, we applied HES analysis to individual patient data from 4 randomized controlled trials evaluating rFVIIa (recombinant factor VIIa) 80 μg/kg to placebo. - METHODS: - We generated polychotomous strata of HES using absolute growth thresholds (≤0/<6/≥6 mL) and quintiles of percent volume change. The relationship between treatment and HES was assessed using proportional odds models. Differences in subgroups based on baseline volume (≥ or <20 mL), and time from symptom onset to treatment (≤ or >2 hours) were explored with testing for interactions. - RESULTS: - The primary analysis included 721 patients. At 24 hours, 36% (134/369) of rFVIIa-treated patients exhibited no hematoma expansion as compared with 25% of placebo (88/352)-treated patients. Significant expansion (≥6 mL) was reduced by 10% in those treated with rFVIIa-(adjusted common odds ratio [acOR], 0.57 [95% CI, 0.43-0.75]). An examination of percent change similarly showed a shift across the spectrum of expansion (acOR, 0.61 [95% CI, 0.47-0.80]). In both groups, mild-to-moderate expansion was observed in 38% to 47% of patients, depending on the threshold used. Differences in absolute HES between the rFVIIa and placebo groups were more pronounced in patients with baseline hemorrhage volumes ≥20 mL (acOR, 0.48 [95% CI, 0.30-0.76] versus <20 mL: acOR, 0.67 [95% CI, 0.47-0.95]; Pinteraction=0.02). No treatment interaction in patients treated within 2 or after 2 hours from onset was observed (acOR, 0.42 [95% CI, 0.19-0.91 versus >2 hours: acOR, 0.59 [95% CI, 0.44-0.79]; Pinteraction=0.30). - - CONCLUSIONS: - The association between rFVIIa and hematoma growth arrest is most pronounced in patients with larger baseline volumes but is evident across the full spectrum of treated patients. | ||
| 650 | 4 | |a cerebral hemorrhage | |
| 650 | 4 | |a clinical trial | |
| 650 | 4 | |a hematoma | |
| 650 | 4 | |a hemostatics | |
| 650 | 4 | |a patients | |
| 700 | 1 | |a Mayer, Stephan A. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Steiner, Thorsten |d 1961- |e VerfasserIn |0 (DE-588)118107623 |0 (DE-627)079247407 |0 (DE-576)291718779 |4 aut | |
| 700 | 1 | |a Broderick, Joseph P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dowlatshahi, Dar |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Stroke |d New York, NY : Association, 1970 |g 54(2023), 12 vom: Dez., Seite 2990-2998 |h Online-Ressource |w (DE-627)266879985 |w (DE-600)1467823-8 |w (DE-576)075145731 |x 1524-4628 |7 nnas |a Exploring hematoma expansion shift with recombinant factor VIIa a pooled analysis of 4 randomized controlled trials |
| 773 | 1 | 8 | |g volume:54 |g year:2023 |g number:12 |g month:12 |g pages:2990-2998 |g extent:9 |a Exploring hematoma expansion shift with recombinant factor VIIa a pooled analysis of 4 randomized controlled trials |
| 856 | 4 | 0 | |u https://doi.org/10.1161/STROKEAHA.123.043209 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.ahajournals.org/doi/10.1161/STROKEAHA.123.043209 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20240408 | ||
| 993 | |a Article | ||
| 994 | |a 2023 | ||
| 998 | |g 118107623 |a Steiner, Thorsten |m 118107623:Steiner, Thorsten |d 910000 |d 911100 |d 50000 |e 910000PS118107623 |e 911100PS118107623 |e 50000PS118107623 |k 0/910000/ |k 1/910000/911100/ |k 0/50000/ |p 3 | ||
| 999 | |a KXP-PPN1885254652 |e 4508465358 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"id":{"eki":["1885254652"],"doi":["10.1161/STROKEAHA.123.043209"]},"origin":[{"dateIssuedDisp":"Dec 2023","dateIssuedKey":"2023"}],"name":{"displayForm":["Vignan Yogendrakumar, MD, MSc; Stephan A. Mayer, MD; Thorsten Steiner, MD, PhD; Joseph P. Broderick, MD; Dar Dowlatshahi, MD, PhD"]},"relHost":[{"id":{"issn":["1524-4628"],"eki":["266879985"],"zdb":["1467823-8"]},"origin":[{"dateIssuedDisp":"1970-","publisher":"Association ; Lippincott Williams & Wilkins","dateIssuedKey":"1970","publisherPlace":"New York, NY ; Philadelphia, Pa."}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"subtitle":"journal of the American Heart Association","title":"Stroke","title_sort":"Stroke"}],"corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"American Heart Association"}],"language":["eng"],"recId":"266879985","type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 29.06.04"],"disp":"Exploring hematoma expansion shift with recombinant factor VIIa a pooled analysis of 4 randomized controlled trialsStroke","part":{"pages":"2990-2998","issue":"12","year":"2023","extent":"9","volume":"54","text":"54(2023), 12 vom: Dez., Seite 2990-2998"},"pubHistory":["1.1970 -"]}],"physDesc":[{"extent":"9 S."}],"title":[{"title":"Exploring hematoma expansion shift with recombinant factor VIIa","subtitle":"a pooled analysis of 4 randomized controlled trials","title_sort":"Exploring hematoma expansion shift with recombinant factor VIIa"}],"person":[{"given":"Vignan","family":"Yogendrakumar","role":"aut","roleDisplay":"VerfasserIn","display":"Yogendrakumar, Vignan"},{"given":"Stephan A.","family":"Mayer","role":"aut","roleDisplay":"VerfasserIn","display":"Mayer, Stephan A."},{"role":"aut","display":"Steiner, Thorsten","roleDisplay":"VerfasserIn","given":"Thorsten","family":"Steiner"},{"role":"aut","display":"Broderick, Joseph P.","roleDisplay":"VerfasserIn","given":"Joseph P.","family":"Broderick"},{"given":"Dar","family":"Dowlatshahi","role":"aut","roleDisplay":"VerfasserIn","display":"Dowlatshahi, Dar"}],"recId":"1885254652","language":["eng"],"note":["Veröffentlicht am 8. Oktober 2023","Gesehen am 08.04.2024"],"type":{"bibl":"article-journal","media":"Online-Ressource"}} | ||
| SRT | |a YOGENDRAKUEXPLORINGH2023 | ||